Praxis Precision Medicines halted its registrational EMBOLD Phase 2/3 study of relutrigine in developmental and epileptic encephalopathies after an interim analysis showed efficacy, prompting a sharp spike in the company’s share price. The trial stop followed prespecified criteria for early success. Regulatory pathways for rare epilepsy indications often allow accelerated moves when convincing efficacy signals emerge. Investors and competitors will monitor full dataset release and FDA interactions to assess chances for expedited approval and commercial positioning in the DEE market. For context: DEEs are a group of severe, treatment‑resistant epilepsy syndromes with high unmet need.